Bicara Therapeutics
BCAX
Bicara Therapeutics (BCAX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.82
- EPS estimate
- −$0.82
- EPS surprise
- −0.02%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 11, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | −$0.82 | −$0.82 | −0.02% | $0.00 | SEC |
| Q1 2026 | May 11, 2026 | −$0.65 | −$0.93 | −43.23% | $0.00 | SEC |
| Q4 2025 | Mar 30, 2026 | −$0.67 | −$0.68 | −1.16% | $0.00 | SEC |
| Q3 2025 | Nov 10, 2025 | −$0.54 | −$0.67 | −23.82% | $0.00 | SEC |
| Q2 2025 | Aug 12, 2025 | −$0.55 | −$0.50 | +9.75% | $0.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.42 | −$0.68 | −63.86% | $0.00 | SEC |
| Q4 2024 | Mar 27, 2025 | −$0.33 | −$0.39 | −18.47% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.41 | −$1.60 | −290.24% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Bicara Therapeutics (BCAX) last report earnings?
Bicara Therapeutics last reported on Aug 11, 2026, covering fiscal Q2 2026.
Did BCAX beat earnings estimates?
No. Bicara Therapeutics reported EPS of −$0.82 for Q2 2026 against a −$0.82 estimate — a 0.02% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.